We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
New insight into epirubicin cardiac toxicity: competing risks analysis of 1097 breast cancer patients.
- Authors
Ryberg, Marianne; Nielsen, Dorte; Cortese, Giuliana; Nielsen, Gitte; Skovsgaard, Torben; Andersen, Per Kragh
- Abstract
Current recommendations that cancer patients receive a maximum cumulative dose of 900 mg/m(2) epirubicin are based on the risk of epirubicin-mediated cardiotoxicity and do not take into account the competing risk of death from cancer. Here, we identify risk factors for cardiotoxicity and overall mortality and determine the cumulative dose of epirubicin that yields a 5% risk for cardiotoxicity for cancer patients from different risk backgrounds.
- Publication
Journal of the National Cancer Institute, 2008, Vol 100, Issue 15, p1058
- ISSN
1460-2105
- Publication type
Journal Article
- DOI
10.1093/jnci/djn206